NCT04656730View on ClinicalTrials.gov

Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas

PHASE4CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Irritable Bowel SyndromeFunctional Dyspepsia
Interventions
DRUG

Iberogast® and Iberogast® N

Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,

Trial Locations (2)

08916

Germans Trias i Pujol Hospital, Badalona

08035

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
collaborator

Bayer Hispania, S.L

UNKNOWN

lead

Hospital Vall d'Hebron

OTHER

NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas | Biotech Hunter | Biotech Hunter